ANAPTYSBIO INC (ANAB) Fundamental Analysis & Valuation

NASDAQ:ANAB • US0327241065

Current stock price

65.54 USD
+3.41 (+5.49%)
At close:
65.3 USD
-0.24 (-0.37%)
Pre-Market:

This ANAB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. ANAB Profitability Analysis

1.1 Basic Checks

  • In the past year ANAB has reported negative net income.
  • ANAB had a positive operating cash flow in the past year.
  • ANAB had negative earnings in each of the past 5 years.
  • ANAB had negative operating cash flow in 4 of the past 5 years.
ANAB Yearly Net Income VS EBIT VS OCF VS FCFANAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M

1.2 Ratios

  • The Return On Assets of ANAB (-3.63%) is better than 85.69% of its industry peers.
  • With a decent Return On Equity value of -35.56%, ANAB is doing good in the industry, outperforming 70.79% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 11.61%, ANAB belongs to the top of the industry, outperforming 94.58% of the companies in the same industry.
Industry RankSector Rank
ROA -3.63%
ROE -35.56%
ROIC 11.61%
ROA(3y)-23.27%
ROA(5y)-19.98%
ROE(3y)-142.07%
ROE(5y)-98.31%
ROIC(3y)N/A
ROIC(5y)N/A
ANAB Yearly ROA, ROE, ROICANAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150 -200

1.3 Margins

  • ANAB has a better Operating Margin (20.42%) than 93.42% of its industry peers.
  • The Profit Margin and Gross Margin are not available for ANAB so they could not be analyzed.
Industry RankSector Rank
OM 20.42%
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANAB Yearly Profit, Operating, Gross MarginsANAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. ANAB Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ANAB is still creating some value.
  • The number of shares outstanding for ANAB has been reduced compared to 1 year ago.
  • ANAB has more shares outstanding than it did 5 years ago.
  • ANAB has a worse debt/assets ratio than last year.
ANAB Yearly Shares OutstandingANAB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
ANAB Yearly Total Debt VS Total AssetsANAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 2.59 indicates that ANAB is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 2.59, ANAB is in the better half of the industry, outperforming 66.54% of the companies in the same industry.
  • ANAB has a debt to FCF ratio of 14.10. This is a negative value and a sign of low solvency as ANAB would need 14.10 years to pay back of all of its debts.
  • The Debt to FCF ratio of ANAB (14.10) is better than 89.94% of its industry peers.
  • ANAB has a Debt/Equity ratio of 7.43. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of ANAB (7.43) is worse than 82.20% of its industry peers.
Industry RankSector Rank
Debt/Equity 7.43
Debt/FCF 14.1
Altman-Z 2.59
ROIC/WACC1.03
WACC11.31%
ANAB Yearly LT Debt VS Equity VS FCFANAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 9.07 indicates that ANAB has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 9.07, ANAB is doing good in the industry, outperforming 76.21% of the companies in the same industry.
  • A Quick Ratio of 9.07 indicates that ANAB has no problem at all paying its short term obligations.
  • ANAB's Quick ratio of 9.07 is fine compared to the rest of the industry. ANAB outperforms 76.21% of its industry peers.
Industry RankSector Rank
Current Ratio 9.07
Quick Ratio 9.07
ANAB Yearly Current Assets VS Current LiabilitesANAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ANAB Growth Analysis

3.1 Past

  • ANAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 90.02%, which is quite impressive.
  • ANAB shows a strong growth in Revenue. In the last year, the Revenue has grown by 157.01%.
  • Measured over the past years, ANAB shows a very strong growth in Revenue. The Revenue has been growing by 25.62% on average per year.
EPS 1Y (TTM)90.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%319.44%
Revenue 1Y (TTM)157.01%
Revenue growth 3Y183.56%
Revenue growth 5Y25.62%
Sales Q2Q%151.08%

3.2 Future

  • Based on estimates for the next years, ANAB will show a very strong growth in Earnings Per Share. The EPS will grow by 56.59% on average per year.
  • Based on estimates for the next years, ANAB will show a quite strong growth in Revenue. The Revenue will grow by 18.35% on average per year.
EPS Next Y-797.23%
EPS Next 2Y-225.17%
EPS Next 3Y-82.96%
EPS Next 5Y56.59%
Revenue Next Year-35.67%
Revenue Next 2Y-8.16%
Revenue Next 3Y7.12%
Revenue Next 5Y18.35%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ANAB Yearly Revenue VS EstimatesANAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
ANAB Yearly EPS VS EstimatesANAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10 15

More info and screens

Find the best growth stocksShow best growing peers

2

4. ANAB Valuation Analysis

4.1 Price/Earnings Ratio

  • ANAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ANAB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANAB Price Earnings VS Forward Price EarningsANAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

  • ANAB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ANAB is cheaper than 91.30% of the companies in the same industry.
  • ANAB's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ANAB is cheaper than 91.10% of the companies in the same industry.
Industry RankSector Rank
P/FCF 96.09
EV/EBITDA 36.65
ANAB Per share dataANAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

  • ANAB's earnings are expected to decrease with -82.96% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-225.17%
EPS Next 3Y-82.96%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ANAB Dividend Analysis

5.1 Amount

  • No dividends for ANAB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ANAB Fundamentals: All Metrics, Ratios and Statistics

ANAPTYSBIO INC

NASDAQ:ANAB (4/8/2026, 8:16:14 PM)

Premarket: 65.3 -0.24 (-0.37%)

65.54

+3.41 (+5.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-03
Earnings (Next)05-04
Inst Owners104.8%
Inst Owner Change0%
Ins Owners2.78%
Ins Owner Change0.9%
Market Cap1.88B
Revenue(TTM)234.60M
Net Income(TTM)-13.23M
Analysts85.26
Price Target79.82 (21.79%)
Short Float %17.71%
Short Ratio9.24
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)100.23%
Min EPS beat(2)65.04%
Max EPS beat(2)135.42%
EPS beat(4)3
Avg EPS beat(4)53.78%
Min EPS beat(4)-0.12%
Max EPS beat(4)135.42%
EPS beat(8)5
Avg EPS beat(8)28.93%
EPS beat(12)8
Avg EPS beat(12)18.55%
EPS beat(16)9
Avg EPS beat(16)8%
Revenue beat(2)2
Avg Revenue beat(2)194.25%
Min Revenue beat(2)15.29%
Max Revenue beat(2)373.21%
Revenue beat(4)4
Avg Revenue beat(4)138.93%
Min Revenue beat(4)15.29%
Max Revenue beat(4)373.21%
Revenue beat(8)7
Avg Revenue beat(8)168.71%
Revenue beat(12)10
Avg Revenue beat(12)134.95%
Revenue beat(16)10
Avg Revenue beat(16)85.85%
PT rev (1m)21.16%
PT rev (3m)37.28%
EPS NQ rev (1m)10.27%
EPS NQ rev (3m)12.07%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.16%
Revenue NQ rev (1m)7.56%
Revenue NQ rev (3m)6.14%
Revenue NY rev (1m)8.72%
Revenue NY rev (3m)1.44%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.03
P/FCF 96.09
P/OCF 95.66
P/B 50.64
P/tB 50.64
EV/EBITDA 36.65
EPS(TTM)-0.52
EYN/A
EPS(NY)-4.67
Fwd EYN/A
FCF(TTM)0.68
FCFY1.04%
OCF(TTM)0.69
OCFY1.05%
SpS8.16
BVpS1.29
TBVpS1.29
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -3.63%
ROE -35.56%
ROCE 14.7%
ROIC 11.61%
ROICexc 267.75%
ROICexgc 267.75%
OM 20.42%
PM (TTM) N/A
GM N/A
FCFM 8.36%
ROA(3y)-23.27%
ROA(5y)-19.98%
ROE(3y)-142.07%
ROE(5y)-98.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 7.43
Debt/FCF 14.1
Debt/EBITDA 5.71
Cap/Depr 15.56%
Cap/Sales 0.04%
Interest Coverage 0.6
Cash Conversion 40.65%
Profit Quality N/A
Current Ratio 9.07
Quick Ratio 9.07
Altman-Z 2.59
F-Score6
WACC11.31%
ROIC/WACC1.03
Cap/Depr(3y)66.14%
Cap/Depr(5y)94.46%
Cap/Sales(3y)1.71%
Cap/Sales(5y)2.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%319.44%
EPS Next Y-797.23%
EPS Next 2Y-225.17%
EPS Next 3Y-82.96%
EPS Next 5Y56.59%
Revenue 1Y (TTM)157.01%
Revenue growth 3Y183.56%
Revenue growth 5Y25.62%
Sales Q2Q%151.08%
Revenue Next Year-35.67%
Revenue Next 2Y-8.16%
Revenue Next 3Y7.12%
Revenue Next 5Y18.35%
EBIT growth 1Y141.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-123.14%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y114.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y114.55%
OCF growth 3YN/A
OCF growth 5YN/A

ANAPTYSBIO INC / ANAB Fundamental Analysis FAQ

What is the fundamental rating for ANAB stock?

ChartMill assigns a fundamental rating of 4 / 10 to ANAB.


Can you provide the valuation status for ANAPTYSBIO INC?

ChartMill assigns a valuation rating of 2 / 10 to ANAPTYSBIO INC (ANAB). This can be considered as Overvalued.


How profitable is ANAPTYSBIO INC (ANAB) stock?

ANAPTYSBIO INC (ANAB) has a profitability rating of 3 / 10.


What is the expected EPS growth for ANAPTYSBIO INC (ANAB) stock?

The Earnings per Share (EPS) of ANAPTYSBIO INC (ANAB) is expected to decline by -797.23% in the next year.